Nasopharyngeal Diseases
Welcome,         Profile    Billing    Logout  
 25 Companies   48 Products   48 Products   0 Mechanisms of Action   1 Trial   217 News 


«12345»
  • ||||||||||  Clinical data, Enrollment change, Trial termination, Trial primary completion date:  NP01: Photon/Proton Radiation Therapy for Carcinoma of the Nasopharynx (clinicaltrials.gov) -  Aug 12, 2015   
    P=N/A,  N=9, Terminated, 
    Completed --> Active, not recruiting N=174 --> 9 | Recruiting --> Terminated | Trial primary completion date: Oct 2056 --> Jul 2015; Slow enrollment, Feasibility issues
  • ||||||||||  Trial completion:  Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli (clinicaltrials.gov) -  Aug 6, 2015   
    P=N/A,  N=50, Completed, 
    N=174 --> 9 | Recruiting --> Terminated | Trial primary completion date: Oct 2056 --> Jul 2015; Slow enrollment, Feasibility issues Not yet recruiting --> Completed
  • ||||||||||  OPB-51602 / Otsuka
    Biomarker, Enrollment change, Trial termination, Trial primary completion date, Metastases:  OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy (clinicaltrials.gov) -  Jun 20, 2015   
    P1,  N=9, Terminated, 
    Recruiting --> Completed | N=200 --> 75 N=45 --> 9 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> May 2015; Lactic and metabolic acidosis of OPB-51602 is not tolerable
  • ||||||||||  Aqupla (nedaplatin) / Simcere
    Enrollment change, Trial termination, Trial primary completion date:  NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation (clinicaltrials.gov) -  Jun 15, 2015   
    P2,  N=10, Terminated, 
    N=45 --> 9 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> May 2015; Lactic and metabolic acidosis of OPB-51602 is not tolerable N=66 --> 10 | Recruiting --> Terminated | Trial primary completion date: Sep 2014 --> Sep 2015; slow patient enrollment
  • ||||||||||  TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
    Trial primary completion date, Metastases:  Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Jun 11, 2015   
    P2,  N=39, Recruiting, 
    N=66 --> 10 | Recruiting --> Terminated | Trial primary completion date: Sep 2014 --> Sep 2015; slow patient enrollment Trial primary completion date: Dec 2014 --> Dec 2015
  • ||||||||||  Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
    Trial primary completion date:  Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Jun 11, 2015   
    P=N/A,  N=10, Active, not recruiting, 
    Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Feb 2014 --> Jan 2016
  • ||||||||||  gefitinib / Generic mfg., docetaxel / Generic mfg.
    Trial termination, Metastases:  Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer (clinicaltrials.gov) -  May 7, 2015   
    P3,  N=270, Terminated, 
    N=150 --> 49 Completed --> Terminated; It was unlikely that the primary endpoint would be reached based on the fifth interim analysis results.
  • ||||||||||  Inlyta (axitinib) / Pfizer
    Trial primary completion date, Metastases:  Nasopharyngeal Carcinoma (NPC) Axitinib (clinicaltrials.gov) -  Dec 12, 2014   
    P2,  N=37, Recruiting, 
    Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Dec 2014 --> Jun 2015
  • ||||||||||  oxycodone controlled release / Generic mfg.
    Clinical data:  Early Use of Opioid in Radiation Mucositis (clinicaltrials.gov) -  Dec 5, 2014   
    P=N/A,  N=174, Not yet recruiting, 
  • ||||||||||  carboplatin / Generic mfg., gemcitabine / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date, Metastases:  Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Nov 23, 2014   
    P2,  N=18, Completed, 
    Trial primary completion date: Dec 2012 --> Dec 2014 Recruiting --> Completed | N=52 --> 18 | Trial primary completion date: Dec 2010 --> May 2011
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date, Surgery:  Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer (clinicaltrials.gov) -  Nov 10, 2014   
    P=N/A,  N=7, Terminated, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2014 N=30 --> 7 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Nov 2014; The study will be rewritten as a data registry study
  • ||||||||||  Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
    Enrollment change, Trial termination, Trial primary completion date:  SOX as Salvage Treatment in Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Aug 21, 2014   
    P2,  N=16, Terminated, 
    Completed --> Terminated; Due to a lack of funding N=48 --> 16 | Recruiting --> Terminated | Trial primary completion date: Jul 2013 --> Dec 2014; poor accrual of eligible patients
  • ||||||||||  MK-2206 / Merck (MSD)
    Trial primary completion date, Metastases:  MK-2206 in Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) -  May 20, 2014   
    P2,  N=45, Active, not recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: May 2014 --> May 2015
  • ||||||||||  MK-2206 / Merck (MSD)
    Trial completion date, Metastases:  MK-2206 in Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) -  May 20, 2014   
    P2,  N=45, Active, not recruiting, 
    Trial primary completion date: May 2014 --> May 2015 Trial completion date: May 2014 --> May 2015